公开(公告)号：US20240327927A1

公开(公告)日：2024-10-03

申请号：US18618857

申请日：2024-03-27

Applicant: IMMUNIS.AI, Inc.

Inventor： Amin I. Kassis ,  Geoffrey Erickson ,  Ricard Henao ,  Kirk Wojno ,  Harry Stylli ,  Leander Van Neste

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present disclosure relates to compositions, methods, and systems useful for assessing whether a patient with prostate cancer is a candidate for active surveillance of the prostate cancer, as well as compositions, methods, and systems for assessing and identifying prostate cancer. The disclosure provides algorithm-based assays comprising subtraction-normalized immunocyte signature profiling from a sample obtained from a prostate cancer patient. Measurement of expression of signature markers identify on an individual basis, via an active surveillance risk score, prostate cancer patients that are to enter, continue, or stop an active surveillance pathway.